Study summary

Adding rituximab to ibrutinib helped people with CXCR4 mutations

Ibrutinib with or without rituximab, pooled analysis · 174 people, pooled analysis · Published September 2025, Blood Advances

72%4-year progression-free with rituximab in CXCR4-mutated WM, vs 43%

What was tested

Patient-level data from three prospective trials comparing ibrutinib plus rituximab with ibrutinib alone in MYD88-mutated WM.

What they found

What it means

Supports routine CXCR4 testing and combination trials.

Blood Adv, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.